tirzepatide 2.2 mg FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price Tirzepatide Weeks 1–4: 2 mg

Pregnant or breastfeeding individuals should only proceed with medical approval

They have stability data supporting that timeline for their specific formulation

Semaglutide Weight Loss for Women and Men Leveraging GLP-1 Technology for Safe and Significant Fat Loss Semaglutide has revolutionized the treatment of obesity, providing a powerful, once-weekly injectable solution that targets the hormonal pathways responsible for regulating appetite and metabolism

Research published in major obesity journals shows that patients on continuous GLP-1 therapy for 1224 months achieve weight losses of 1522% of body weight, compared to 23% in placebo groups